In the reply to the Letter to the Editor entitled “Dextromethorphan-Quinidine for Agitation in Alzheimer Disease,” published in the March 15, 2016, issue of JAMA,1 a financial disclosure contained an erroneous name. The second-to-last sentence of the Conflict of Interest Disclosures should have read “Dr Siffert reported being a full-time employee of Avanir Pharmaceuticals and may hold stock or options.” This article was corrected online.
Incorrect Name in Conflict of Interest Disclosure. JAMA. 2016;315(15):1661. doi:10.1001/jama.2016.3949